Regulatory Milestones and Health Advances: Key Developments in the Pharmaceutical Sector

Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an obesity-related heart condition, while the US FDA approves several new treatments. Additionally, the US FTC sues major pharmacy benefit managers over insulin prices, and efforts are ongoing to tackle the mpox outbreak in Burundi.

In the latest updates on health news, the European Medicines Agency has recommended Novo Nordisk's Wegovy for managing heart failure in obese individuals, marking its second supported use beyond weight loss. Novo's case for the drug's versatile health benefits grows stronger.

Meanwhile, the U.S. Food and Drug Administration has greenlit Zevra Therapeutics' drug for a rare, deadly genetic disorder, after years of efforts by the company. The FDA also approved AstraZeneca's self-administered nasal spray flu vaccine, the first of its kind.

On the legal front, the U.S. Federal Trade Commission has filed a lawsuit against the nation's top three pharmacy benefit managers, accusing them of inflating insulin prices to benefit from pharmaceutical rebates. In Burundi, UNICEF emphasizes the importance of combating stigma to control the mpox outbreak.

(With inputs from agencies.)